Jalil, 2020 - Google Patents
The Development Of Multivalent Nano-Self Peptides As Antagonists For Antibody-Dependent Macrophage PhagocytosisJalil, 2020
View PDF- Document ID
- 13364110968005880043
- Author
- Jalil A
- Publication year
External Links
Snippet
Macrophages are immune cells that are capable of physically engulfing and clearing whole cells and particles. This process of phagocytosis is modulated by an important interaction between membrane protein CD47, present on all 'self'cells, and the macrophage immune …
- 210000002540 Macrophages 0 title abstract description 263
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy | |
| JP7575102B2 (en) | MUC18-specific antibodies | |
| KR102776145B1 (en) | Anti-BCMA polypeptides and proteins | |
| JP7656330B2 (en) | CD44-specific antibodies | |
| WO2020016662A2 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
| JP7623939B2 (en) | Antibodies specific for the folate receptor alpha | |
| JP7578289B2 (en) | MUC18-specific antibodies | |
| WO2022100590A1 (en) | Adcc-enhanced humanized antibody for claudin 18a2 and application thereof | |
| KR20220004653A (en) | Effluent pump-cancer antigen multispecific antibodies and compositions, reagents, kits and methods related thereto | |
| WO2016133059A1 (en) | Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same | |
| US20250313631A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| US20250122303A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| CN109689691A (en) | IFN-γ-inductivity regulatory T-cell can convertibility anticancer (IRTCA) antibody and its application | |
| US20250333515A1 (en) | Binding agents and methods of use thereof | |
| Jalil | The Development Of Multivalent Nano-Self Peptides As Antagonists For Antibody-Dependent Macrophage Phagocytosis | |
| KR20240006519A (en) | Anti-SIGLEC compositions and uses thereof | |
| KR20230158058A (en) | Antibodies specific for sialic acid-binding IG-like lectin 15 and uses thereof | |
| CN114630679A (en) | Combination of anti-GARP antibodies and immunomodulators | |
| EP4494655A1 (en) | Combination of multi-specific molecule and immune checkpoint inhibitor | |
| TW202535920A (en) | Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and application thereof | |
| HK40105152A (en) | Antibodies specific to muc18 | |
| HK40115416A (en) | Combination of multi-specific molecule and immune checkpoint inhibitor | |
| EA049996B1 (en) | ANTIBODY TO SIGLEC-10 (VARIANTS) | |
| Balakrishnan et al. | Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen | |
| HK40060753B (en) | Antibodies specific to muc18 |